INTRAPERITONEAL AND INCISIONAL BUPIVACAINE ANALGESIA FOR MAJOR ABDOMINAL/GYNECOLOGIC SURGERY: A PLACEBO-CONTROLLED TRIAL

S. ATASHKHOII, M.D.,* M. JAFARI SHOBEIRI, M.D.,** AND R. AZARFARIN, M.D.*

From the Depts. of *Anesthesiology and **Obstetrics and Gynecology, Tabriz University of Medical Sciences, Tabriz, I.R. Iran.

ABSTRACT

Background: Postoperative pain is an important surgical problem. Recent studies in pain pathophysiology have led to the hypothesis that with perioperative administration of analgesics (pre-emptive analgesia) it may be possible to prevent or reduce postoperative pain. This study was planned to investigate the efficacy of pre-emptive analgesia on postoperative pain after major gynecologic abdominal surgeries.

Methods: In this prospective, double-blinded, randomized, and placebo-controlled trial, 60 ASA physical status I and II patients undergoing major abdominal gynecologic surgeries were randomized to receive 45 mL of bupivacaine 0.375% or 45mL of normal saline; 30 mL and 15 mL of the treatment solution was administered into the peritoneal cavity and incision, respectively, before wound closure. The pain score of the patients was evaluated by the visual analogue scale (VAS) on awakening, and at 6, 12, and 24h after surgery. Time to first analgesia request and total analgesic requirements in the first 24h were recorded.

Results: Pain scores were significantly higher in the placebo group than in the bupivacaine group on awakening (5.98±1.01 vs. 1.05±1.05; p<0.001), and at 6h after surgery (5.37±0.85 vs. 2.51±1.02; p=0.001). First request to analgesia was significantly longer in the bupivacaine patients than in the placebo group (5.87±3.04 h vs. 1.35±0.36; p<0.001). Meperidine consumption over 24h was 96.00 ±17.53 mg in the placebo group compared with 23.28 ±14.89 mg in the bupivacaine patients (p<0.001).

Conclusion: A combination of intraperitoneal and incisional bupivacaine infiltration at the end of abdominal gynecologic surgeries reduces postoperative pain on awakening and for 6 hours after surgery, and provides significant opioid-sparing analgesia for 24 h after gynecologic abdominal surgeries.


Keywords: Gynecologic abdominal surgeries, Pre-emptive analgesia, Intraperitoneal infiltration, Bupivacaine

INTRODUCTION

Postoperative pain management is an important component of patient care after gynecologic surgery. Analgesic use strategies in the initial postoperative period commonly include patient-controlled analgesia, and parenteral nonsteroidal anti-inflammatory agents. These strategies address the problem of pain control only after painful stimuli have been initiated. In contrast, pre-emptive analgesia is intervention that is provided before or during operation to reduce or prevent subsequent pain.1, 2

Recent studies demonstrated that pre-emptive parrenteral agent use including ketamine,3 ketorolac,4 promethazine,5 esmolol6 and meloxicum,7 and regional analgesia (with local anesthetics8, 9 or opioids10, 11) reduces pain scores and medication requirements, in many abdominal surgeries. The value of locally applied or inci-
Intraperitoneal and Incisional Bupivacaine for Pain Control

Sixty ASA physical status I or II, 18-65 year old female patients undergoing gynecologic abdominal surgeries, were enrolled in this prospective, randomized, double-blind, and placebo-controlled, clinical trial over six months after obtaining written informed consent. Randomization process of allocating patients into study groups was performed by forming "randomly permuted blocks" in online software (http://www.Randomization.com). Exclusion criteria were history of severe heart, pulmonary, hepatic, renal or psychological disease, or allergy to local anesthetics.

All patients received 5mg oral diazepam 30 minutes before operation. General anesthesia was induced with thiopentone/fentanyl and tracheal intubation. Patients were randomized to receive either 45mL of bupivacaine 0.375% (bupivacaine group, n=30) or 45mL normal saline (placebo group, n=30). Thirty mL and 15 mL of treatment solution were administered into the peritoneal cavity or incision, respectively, before wound closure.

Postoperatively, pain intensity was evaluated usingVAS (0-10 cm) on awakening and at 6, 12, and 24h. A standard postoperative analgesic regimen was utilized in all patients. The patient was prescribed 0.5 mg/kg meperidine IM as required for analgesia or with VAS ≥4.

Sedation level was according to a four-point scale (0=awake and alert; 1=mildly sedated or easily aroused; 2=moderately sedated or can be aroused by shaking; 3=deeply sedated or difficult to arouse, even by shaking). Time to first analgesia request and total analgesic (meperidine and tramadol) requirements at 24h postoperatively, and side effects such as nausea, vomiting, pruritus, and respiratory depression (yes or no) at 24h postoperatively were recorded.

Table I. Demographic and intraoperative variables for patients in the two groups.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Placebo group (n=30)</th>
<th>Bupivacaine group (n=30)</th>
<th>P,</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (year)</td>
<td>41.83±14.80</td>
<td>40.40±14.91</td>
<td>0.71</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>69.27±9.66</td>
<td>69.30±10.69</td>
<td>0.99</td>
</tr>
<tr>
<td>ASA physical status 1/II</td>
<td>20/10</td>
<td>21/9</td>
<td>1.00</td>
</tr>
<tr>
<td>Surgery duration (h)</td>
<td>2.34±0.80</td>
<td>2.45±0.96</td>
<td>0.65</td>
</tr>
<tr>
<td>Type of surgery</td>
<td></td>
<td></td>
<td>0.94</td>
</tr>
<tr>
<td>Cesarean section</td>
<td>4</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Salpingo-ovarectomy due to ectopic pregnancy or ovarian cyst</td>
<td>7</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Radical hysterectomy without nodal dissection</td>
<td>15</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>Radical hysterectomy with nodal dissection</td>
<td>4</td>
<td>3</td>
<td></td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD.

PATIENTS AND METHODS

Statistical analyses were performed using the software package SPSS v12.0 (SPSS. Inc. Chicago. IL). Comparisons of continuous variables were made using independent t test or Mann-Whitney U test. Analyses of nominal variables were made using χ² or Fisher's exact test as appropriate. Repeated measures ANOVA was done to evaluate VAS score changes with time in each study group. The test results were considered significant if p≤0.05.

RESULTS

There was no significant difference in age, weight, ASA class, duration and type of surgery between the patients (Table I).

On awakening and 6h after operation, pain scores were significantly less in the bupivacaine group than in the placebo group (p<0.001). However, at 12h (2.03±1.1 v.s 3.271,30; p=0.16), and 24h (1.29±0.9 v.s 1.79±1.0; p=0.31), there were no differences in pain scores between the two groups (Fig. 1). As shown in Fig. 1 the repeated measures ANOVA of VAS score of patients in the bupivacaine group [F (3, 87) =30.18; p=0.0001], and placebo group [F (3, 87) =276.97; p= 0.0001] revealed that changes with time was significant.

Pain onset time and time to first request to analgesia were significantly longer in the bupivacaine patients (5.30 3.07 h, 5.87 3.04 h; respectively) than in the placebo group (0.99±0.28 h, 1.35±0.36 h; respectively; p< 0.001 for both variables; Table II).

The mean meperidine requirement was significantly smaller in the bupivacaine patients (23.28±14.89 mg) than in the placebo group (96.00±17.53 mg) at 24h postoperatively (p<0.001; Table II). This significant difference was attributable largely to the reduction in meperidine requirements within the first 6h postoperative period. There were no significant differences between the groups in tramadol administration at 24h (p=0.09; Table II).

There were no significant differences between the groups in sedation level (p=0.42; Table II). However, there were significant differences regarding postoperative complications such as nausea, vomiting, pruritus and respiratory depression (p<0.001), and patients who asked for antiemetic (p=0.004) between the two groups at the first 24h after surgery (Table II).
DISCUSSION

The aim of the present study was to investigate whether infiltration of a local anesthetic solution in the surgical field would reduce the incidence, intensity, and duration of postsurgical pain compared with infiltration of saline in patients undergoing gynecologic laparotomy.

A number of previous investigations have examined wound instillation and peritoneal analgesia with local anesthetics. Some studies were unable to demonstrate a benefit of employing this technique in terms of reduction in the patient’s perception of pain.12-17

A qualitative systemic review of the use of incisional local anesthetics for postoperative analgesia after abdominal operations showed that there was improved pain relief after inguinal herniorrhaphy, gynecologic laparoscopy and appendectomy.18-22 For other types of surgery, such as total abdominal hysterectomy (TAH), open cholecystectomy, cesarean delivery, and major upper abdominal surgery, the evidences showing the value of instillation of local anesthetic into the incision are equivocal.12, 17, 28

In the present study, peritoneal combined with subcutaneously delivery of local anesthetic compared with placebo, beneficial effects were observed. In the treatment group, patients had a better pain score on awakening, and 6h postoperatively, and had a longer interval to first analgesia and had reduced opioid requirement in the first 24h postoperatively.

The failure of some of the previous trials to show significant analgesic benefits may be attributed to the site of surgery, timing of the administration, and dose of local anesthetic. In addition it is possible that either incisional or intraperitoneal local anesthetics alone may not be adequate to produce measurable postoperative analgesia. Our data suggest that block of both visceral and somatic conduction is important if an analgesic sparing effect is to be demonstrated after major surgery.27, 28

This method of delivery of local anesthetic is easy, and no expertise or special training is required. It was not associated with any untoward side effects and did not interfere with the operative procedure. It appears to be a valuable adjunct to opioids and have an opioid sparing role.25-28

Bupivacaine has been shown to have an analgesic effect beyond the duration of its pharmacological action. It has been postulated that bupivacaine suppresses the formation of a hyperexcitable state in the central nervous system which is responsible for the maintenance of postoperative pain.27

No adverse effects are detected from the dose of bupivacaine used in previous studies. This observation is consistent with pharmacokinetic studies in which no adverse clinical effects were reported from intraperitoneal bupivacaine. In our study bupivacaine was administered in doses similar to that of these studies and peak plasma concentrations were much smaller than the generally accepted toxic value of 3 μg/mL.27-29 The dose of bupivacaine used was 150 mg in 45 mL bupivacaine 0.375%, which is lower than the maximum dose (175 mg) of drug for infiltration anesthesia.1

The benefits of reducing meperidine administration are thought to be related to improved recovery from surgery and anesthesia. In the postoperative period, analgesia, sedation, nausea, and return of bowel motility are impor-

---

**Table II.** Postoperative findings in the two groups.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Placebo group (n=30)</th>
<th>Bupivacaine group (n=30)</th>
<th>P,</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain onset time (h)</td>
<td>0.99±0.28</td>
<td>5.50±3.07</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Time to first analgesia (h)</td>
<td>1.35±0.36</td>
<td>5.87±3.04</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cumulative meperidine dose (mg)</td>
<td>96.00±17.53</td>
<td>23.28±14.89</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cumulative tramadol dose (mg)</td>
<td>75.50±6.30</td>
<td>64.84±5.80</td>
<td>0.09</td>
</tr>
<tr>
<td>Sedation level</td>
<td></td>
<td></td>
<td>0.42</td>
</tr>
<tr>
<td>0</td>
<td>26</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>4</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Side effects</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Nausea</td>
<td>15</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td>9</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Pruritus</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Respiratory depression</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Antiemetic given (first 24h)</td>
<td>0</td>
<td>0</td>
<td>0.004</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD
tant factors that facilitate recovery. In this study, the application of intraperitoneal and subcutaneous bupivacaine was associated with lower pain scores and a reduction in meperidine requirements in the first 24 hours after surgery. Furthermore, there was little nausea and vomiting in the 24-hour period.

We conclude that pre-emptive incisional and intraperitoneal bupivacaine may be recommended because it reduced pain on awakening and 6h postoperatively, and provided significant supplemental opioid-sparing analgesia for 24 hours after major gynecologic abdominal surgeries.

REFERENCES